Is Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)
Jul 09, 2018•13 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast